I will admit that I am not a stock chartist nor am I an investor who typically trades based on technical trends. With that disclosure, aren't we really waiting for news that confirms the business model and the promise of revenues generated on a global basis from what we hope is ground breaking technology? As a penny stock trading at relatively low volumes (and certainly low dollar numbers), while the moving averages may be a datapoint, my view is that the real move in this stock will be news driven and, if we get what a lot of us expect in the PRs including announcements of some major contracts, the stock price should blow through any narrow ranges and/or technical barriers. I have been in this stock since the private offerings (at a loss on those shares), but thanks to very helpful diligence from Rainmaker and others, I had the confidence to keep building positions after the Favrille transaction. I now own more shares than I should but, based on everything I am now reading and what is occurring with the almost certain advent of broad-based electronic medical records, I am very optimistic that we are on the cusp of confirmation that we are on the ground floor of a great investment.
One question for the Board and I may have missed something. There was a lot of consternation about the financing relationship with Duchess, apparently with some basis. Did anything replace that relationship after it was cancelled? Thanks.
AI
